CTOs on the Move

Farnes Enterprises Corporation

www.medsource-direct.com

 
Farnes Enterprises Corporation is a Woods Cross, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Physio-Control

Physio-Control, now part of Stryker, is the world leader in the development, manufacture, sale and service of external defibrillator/monitors and emergency medical response products and services. We envision a world in which no person dies suddenly as a result of an acute, treatable medical event. Physio-Control Team Members are part of a unique group who love what they do - and why they do it. Our Team is comprised of talented individuals who have purpose, creativity and passion, and we are proud to be leading the industry dedicated to saving and extending lives around the globe. Our Team Members are our most valuable asset and what sets us apart from our competitors. We are committed to our mission to save lives through hard work and dedication.

DGH Technology

DGH Technology is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biomerica

Biomerica is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smith and Nephew

Smith and Nephew is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.